Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bupivacaine
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : University of California
Deal Size : Undisclosed
Deal Type : Collaboration
OncoZenge Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge
Details : The partnership focuses on a patient engagement study in managing oral mucositis pain, while exploring potential pathways toward a future IND application for BupiZenge.
Product Name : BupiZenge
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 17, 2025
Lead Product(s) : Bupivacaine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : University of California
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Baltic Sea Foundation
Deal Size : $8.3 million
Deal Type : Financing
OncoZenge Secures Approximately SEK 70 Million in Financing Ahead of spin-off and separate listing
Details : OncoZenge is developing the BUPI project under the BupiZenge ® brand , for the treatment of pain due to oral mucositis, a serious side effect of cancer treatment. BupiZenge ® has shown promising results in a phase 2 study. The capital will be used to f...
Product Name : BupiZenge
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 16, 2020
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Baltic Sea Foundation
Deal Size : $8.3 million
Deal Type : Financing